RXRX — Recursion Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.08bn
- $1.78bn
- $44.58m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -61.9 | -87 | -186 | -239 | -328 |
Depreciation | |||||
Non-Cash Items | 0.886 | 6.33 | 19.8 | 39.3 | 66.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.408 | 30.8 | -0.306 | 105 | -50.3 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -57 | -45.4 | -159 | -83.5 | -288 |
Capital Expenditures | -3.91 | -5.83 | -39.8 | -37.1 | -12 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | -2.91 | -232 | 230 | 1.73 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -3.91 | -8.74 | -272 | 193 | -10.2 |
Financing Cash Flow Items | -0.275 | 0 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 120 | 246 | 459 | 154 | 140 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 59.5 | 192 | 28.2 | 264 | -158 |